Browsing by Subject "Nivolumab plus Ipilimumab"
Now showing items 1-1 of 1
-
Assessing therapeutic safety and efficacy of Pazopanib, Pembrolizumab plus Axitinib and Nivolumab plus Ipilimumab in Renal Cell Carcinoma: a systematic review and meta-analysis
(Brac University, 2023-11)Renal cell carcinoma (RCC) is the predominant form of kidney cancer. It is a highly prevalent form of solid tumor, and the limited availability of accurate disease models has impeded progress in the field of human kidney ...
